csirt@kutim:~/threat-intel/cve/CVE-2021-1566

Katalog CVE

CVSS 7.4 · High EPSS 0,67%

Kerentanan Improper Following of a Certificate's Chain of Trust pada cisco email security appliance, cisco asyncos +1 lainnya. Skor CVSS 3.1 7.4 (High) menurut NVD.

Deskripsi (NVD)

A vulnerability in the Cisco Advanced Malware Protection (AMP) for Endpoints integration of Cisco AsyncOS for Cisco Email Security Appliance (ESA) and Cisco Web Security Appliance (WSA) could allow an unauthenticated, remote attacker to intercept traffic between an affected device and the AMP servers. This vulnerability is due to improper certificate validation when an affected device establishes TLS connections. A man-in-the-middle attacker could exploit this vulnerability by sending a crafted TLS packet to an affected device. A successful exploit could allow the attacker to spoof a trusted host and then extract sensitive information or alter certain API requests.

Rincian

Terbit di NVD
16 Juni 2021
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
7.4 (High), sumber NVD
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-296: Improper Following of a Certificate's Chain of Trust
CWE-295: Improper Certificate Validation
EPSS (30 hari)
0,67% peluang dieksploitasi; lebih tinggi dari 50,6% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
cisco email security appliance Semua versi
cisco asyncos Semua versi sebelum 12.5.3-035
cisco asyncos Versi 13.0 hingga sebelum 13.0.0-030
cisco asyncos Versi 13.5 hingga sebelum 13.5.3-010
cisco web security appliance Semua versi
cisco asyncos Semua versi sebelum 11.8.3-021
cisco asyncos Versi 12.0.0 hingga sebelum 12.0.3-005
cisco asyncos Versi 12.5.0 hingga sebelum 12.5.1-043

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.